Jun 30, 2014
FDA approves Alcobra’s protocol for Phase IIb study of metadoxine drug candidate
Metadoxine
Alcobra Ltd.
http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda-approves-alcobras-protocol-for-phase-iib-study-of-metadoxine-drug-candidate-090514-4262995
Israel-based Alcobra has received approval from the US Food and Drug Administration (FDA) for its protocol for planned Phase IIb clinical study of Metadoxine Extended Release (MDX) drug candidate for the…
View On WordPress